

Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes mellitus

Systematic review and network meta–analysis

Running title: SGLT2 inhibitors in type 2 diabetes

Francesco Zaccardi

David R Webb

Zin Z Htike

Dalia Youssef

Kamlesh Khunti

Melanie J Davies

Diabetes Research Centre, University of Leicester, Leicester, UK

Leicester Diabetes Centre, UHL NHS Trust, Gwendolen Road, Leicester LE5 4PW, UK

Corresponding Author

Dr Francesco Zaccardi

Diabetes Research Centre, Leicester General Hospital, Leicester, UK

Phone: +44 0116 258 4389 – Fax: +44 0116 258 4499

Email: frazac@fastwebnet.it

Word Count: Abstract 278; Main Text 3515

References: 74

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1111/dom.12670](https://doi.org/10.1111/dom.12670)

Tables: 3

Figures: 2

Supplementary Appendix: Search strategy; 8 Tables; 8 Figures; PRISMA checklist

Author Manuscript

ABSTRACT

Aims

To assess the comparative efficacy and safety of SGLT2 inhibitors in adults with type 2 diabetes.

Materials and Methods

We electronically searched up to November 3, 2015, randomised controlled trials (e 24 weeks) including canagliflozin, dapagliflozin, or empagliflozin. Data were collected for cardiometabolic and safety outcomes and synthesized with network meta-analyses.

Results

38 trials (23997 participants) were included. Compared to placebo, all SGLT2 inhibitors reduced HbA1c, fasting plasma glucose (FPG), body weight (BW), and blood pressure (BP), and slightly increased HDL-cholesterol. Canagliflozin 300mg reduced HbA1c, FPG, and systolic BP and increased LDL-cholesterol to a greater extent compared to other inhibitors at any dose. At their highest doses, canagliflozin 300mg reduced HbA1c by 0.2% (95% CI: 0.1 to 0.3) compared to both dapagliflozin 10mg and empagliflozin 25mg; FPG by 0.6mmol/l (0.3 to 0.9) and 0.5mmol/l (0.1 to 0.8), vs dapagliflozin and empagliflozin, respectively; systolic BP by 2mmHg (1 to 3) vs dapagliflozin; and increased LDL-cholesterol of 0.13mmol/l (0.03 to 0.23) and 0.15mmol/l (0.06 to 0.23) vs dapagliflozin and empagliflozin, respectively; highest doses of inhibitors had similar effects on BW reduction. Canagliflozin 300mg and 100mg increased the risk of hypoglycaemia compared to placebo, dapagliflozin 10mg, and empagliflozin 10mg (odds ratios (ORs), 1.4 to 1.6). Dapagliflozin 10mg increased the risk of urinary tract infection compared to placebo and empagliflozin 25mg

(ORs, 1.4). All inhibitors similarly increased the risk of genital infection (ORs, 4 to 6 compared to placebo).

Conclusions

Although increasing the risk of genital infection, SGLT2 inhibitors are effective in improving cardiometabolic markers in type 2 diabetes, with canagliflozin 300mg performing better in this respect than other inhibitors. Further studies will clarify whether these differences are likely to translate in different long term outcomes.

INTRODUCTION

Type 2 diabetes mellitus is a complex disorder characterised by hyperglycaemia and progressive dysregulation of insulin–glucose feedback mechanisms [1]. Multiple intervention studies have demonstrated the importance of glucose control in the reduction of long-term microvascular and, to some extent, macrovascular complications of the disease [2].

A range of glucose–lowering treatments are currently available and they exert their main effects by modulating peripheral insulin resistance or β -cell insulin secretion [3]. More recently, a new class of glucose–lowering agents, which act by the inhibition of renal glucose reabsorption in the kidney, has been introduced [4]. In physiological conditions, glycosuria arises when the tubular threshold for glucose reabsorption is exceeded. As sodium–glucose cotransporter 2 (SGLT2) is the major cotransporter involved in tubular glucose reuptake, inhibitors of its activity have been developed with the aim of enhancing glycosuria and reducing blood glucose levels [5].

The efficacy and safety of SGLT2 inhibitors have been investigated in several randomised controlled trials (RCTs), showing improved glucose control and a reduction of body weight and blood pressure with a low risk of hypoglycaemia [5]. These drugs are recommended by the American Diabetes Association and European Association for the Study of Diabetes as a treatment option in patients on metformin with or without another glucose–lowering treatment if the personalised glucose target is not achieved [3]. However, no direct comparisons between specific SGLT2 inhibitors are available to date, thus limiting the possibility of a comparative assessment of their efficacy and safety.

Network meta-analysis is considered the methodology of choice to allow estimation of the comparative effectiveness of multiple treatments when direct ‘head-to-head’ data are unavailable [6]. Further to this, its value to inform health care decision making is increasingly recognised, given the possibility of ranking treatments according to efficacy and safety [7]. Within this context, we

conducted a systematic review and network meta-analysis to assess the comparative efficacy and safety of SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin.

Author Manuscript

MATERIALS AND METHODS

Data Sources and Searches

This study was conducted according to a pre-specified protocol and followed the standard guidelines for conducting and reporting systematic reviews and network meta-analysis (Supplementary Appendix) [8–10]. We searched PubMed, ISI Web of Science, and the Cochrane Library for RCTs published in any language from inception until November 3, 2015 and comparing licensed doses of canagliflozin (100mg or 300mg), dapagliflozin (5mg or 10mg), or empagliflozin (10mg or 25mg) with placebo or other glucose-lowering drugs in adults with type 2 diabetes.

Study Selection

RCTs lasting at least 24 weeks and reporting data on one or more cardiometabolic or safety outcomes were included. We excluded RCTs including only patients with chronic kidney disease at baseline. Cardiometabolic outcomes comprised HbA1c, fasting plasma glucose (FPG), body weight (primary outcomes); systolic and diastolic blood pressure, total cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, and triglycerides. Safety outcomes included all hypoglycaemic events, urinary tract infection, genital infection, diabetic ketoacidosis, and bone fractures. Reference lists of eligible studies, as well as systematic reviews and meta-analyses of SGLT2 inhibitors, were manually scanned for additional relevant studies.

Data Extraction and Quality Assessment

Three authors independently performed the literature search. After the identification of the eligible studies, the three authors independently extracted data, using standardised pre-defined forms, on: first author name, clinical trial registration number, year of journal article publication, background

glucose-lowering therapy, SGLT2 inhibitor(s) and comparator(s), duration of follow-up, sample size, gender distribution, age, diabetes duration, baseline HbA1c, and outcome measured. We extracted outcomes data as arm-specific counts (i.e., number of participants, mean difference and standard error (or standard deviation) for continuous outcomes in patients with baseline and at least one post-baseline measurement); total number of participants and participants with event for dichotomous outcomes in patients who were randomised and received treatment; or contrast-based estimations (i.e., pairwise comparisons). When studies reported outcomes data for different durations of follow-up, the longest was used. We retrieved data from ClinicalTrials.gov when it was not possible to extract relevant information from the published report. In cases where the independent reviewers disagreed on the eligibility of an article or data extraction, consensus was reached by arbitration. Study quality was assessed using the Cochrane risk of bias tool [11].

Data Synthesis and Analysis

We undertook a network meta-analysis within a frequentist model, an alternative to the Bayesian approach. Stata 14.1 (Stata Corp, College Station, TX, USA) was used for all analyses, Pairwise random-effects meta-analyses were performed using the DerSimonian and Laird method [12]. Network meta-analyses were based on the method of multivariate meta-analysis with the assumption that all treatment contrasts have the same heterogeneity variance [13–15]. Results were reported with 95% confidence intervals; we considered $p < 0.05$ as statistically significant.

In three-arm trials reporting contrasted-based estimates for continuous outcomes, pairwise comparisons were available only for two out of the three possible contrasts (i.e., A vs B and B vs C, but not A vs C, where A, B, and C denote the three arms); in these cases, given the presence of correlations between the treatment differences, the standard error (\tilde{A}) of the missing contrast was

estimated using the formula: $\tilde{A}_{AC}^2 = \tilde{A}_{AB}^2 + \tilde{A}_{BC}^2 - 2\tilde{A}_{AB}\tilde{A}_{BC}$ [16]. As \tilde{A} values (correlations) were not reported, we used in the main analysis a value similar to those obtained from other comparable studies included in this systematic review ($\tilde{A}=0.5$), as previously advocated [16]. We performed sensitivity analyses assuming different values of \tilde{A} (0.2, 0.7, and 0.9). Comparable results were obtained and therefore we reported only the results of the main analysis.

We combined linagliptin and sitagliptin in a single group (dipeptidyl peptidase-4 inhibitors, DPP-4i) and glimepiride and gliclazide in another (sulphonylurea). For the primary outcomes, we reported random-effect pairwise meta-analyses with heterogeneity across studies estimated using the I^2 statistic. For dichotomous outcomes, we used odds ratio (OR) as effect measure and added 0.5 when studies reported zero events. For all outcomes, we summarised the evidence by using a network diagram [17]. We reported characteristics and summary data of included studies in tables. We presented results against a common comparator (placebo) in forest plots and showed comparisons across SGLT2 inhibitors in tables [18]; we also displayed graphically with radar plots the ranking probabilities (*network rank* command) for different cardiometabolic and safety outcomes and reported comparison-adjusted funnel plots (*netfunnel* command) to assess the association between study size and result. We assumed that participants of the included RCTs could be randomly allocated to any of the three treatments being compared (on average, the baseline characteristics of participants are similar as the treatments are tested for a wide range of patients). For each network, we assessed consistency between direct and indirect evidence by using the ‘design by treatment’ interaction model [19].

RESULTS

Study characteristics

From 2174 identified records we excluded non-human and observational studies, leaving 79 reports for full-text assessment; after further selection (Figure S1 in the Supplementary Appendix), 38 unique RCTs fulfilled inclusion criteria (Table 1) [20–57]. RCTs were published between 2012 and 2015 included 23997 (range, 136–2072) participants with type 2 diabetes; 34 (89.5%) were multinational RCTs. Baseline HbA1c, age, and disease duration weighted means were 8.1%, 58 years old, and 8 years, respectively; 57% were males and follow up duration ranged from 24 to 208 weeks. Other characteristics of the RCTs, such as study-, drug-, and outcome-specific available data, are reported in Tables S1-S5.

Overall, the risk of bias for the domains included in the Cochrane tool of risk assessment were judged to be low, high, and unclear in 89.5%, 1.8%, and 8.7% of the cases, respectively; high or unclear domain-specific bias was lowest for blinding of outcome assessment (2.7%) and highest for random sequence generation (15.8%) (Table S5, Figure S2). The risk of bias was high or unclear in 1.8%, 10.8%, and 16.7% of canagliflozin, dapagliflozin, and empagliflozin RCTs, respectively. Networks of evidence for all outcomes are graphically displayed in Figure 1.

Meta-analyses

Primary outcomes: HbA1c, fasting plasma glucose, and body weight

Data on HbA1c were available from all RCTs. Direct pairwise random-effects meta-analyses showed significant reductions of HbA1c versus placebo, from -0.9% (95% confidence interval: -1.0 to -0.7) [-9.8mmol/mol; -10.9 to -7.6] for canagliflozin 300mg to -0.6% (-0.7 to -0.4) [-6.5mmol/mol; -7.6 to -4.4] for dapagliflozin 5mg (Figure S3). When compared to other glucose-lowering drugs (sulphonylurea, DPP-4i, or metformin), pairwise differences ranged from a significant reduction of -0.3% (-0.5 to -0.1) [-3.3mmol/mol; -5.4 to -1.1] comparing dapagliflozin 10mg with DPP-4i to a nonsignificant increase of 0.1% (-0.1 to 0.2) [1.1mmol/mol; -1.1 to 2.2] for empagliflozin 10mg versus metformin (Figure S3). The results of the network meta-analysis showed a mean HbA1c reduction, compared to placebo, of -0.9% (-1.0 to -0.8) for canagliflozin 300mg [-9.4mmol/mol; -10.5 to -8.3]; -0.8% (-0.9 to -0.7) for canagliflozin 100mg [-8.3mmol/mol; -9.4 to -7.2]; -0.7% (-0.8 to -0.6) for empagliflozin 25mg [-7.2mmol/mol; -8.3 to -6.1]; -0.7% for dapagliflozin 10mg (-0.7 to -0.6) [-7.2mmol/mol; -8.1 to -6.3]; -0.6% (-0.7 to 0.5) [-6.6mmol/mol; -7.7 to 5.5] for empagliflozin 10mg; and -0.6% (-0.7 to -0.4) [-6.1mmol/mol; -7.3 to 4.8] for dapagliflozin 5mg (Table 2; Figure 2). Comparisons across SGLT2 inhibitors showed greater HbA1c reductions with canagliflozin 300mg compared to all other SGLT2 drugs (from -0.3% [-3.3mmol/mol] versus dapagliflozin 5mg to -0.1% [-1.1mmol/mol] versus canagliflozin 100mg) and no significant differences between dapagliflozin and empagliflozin at different doses (Table 2). Figure S4 and Figure S5 show SGLT2 inhibitors according to the ranking probabilities and the mean rank, respectively.

Values of FPG were available from 37 RCTs. Pairwise random-effects meta-analyses evidenced significant reductions of FPG versus placebo for all SGLT2 inhibitors, from -2.0mmol/l (-2.4 to -1.6) for canagliflozin 300mg to -1.1mmol/l (-1.5 to -0.7) for dapagliflozin 5mg (Figure S3). Comparing

SGLT2 inhibitors to other glucose-lowering drugs, differences ranged from -1.2mmol/l (-1.6 to -0.8) for canagliflozin 300mg versus DPP-4i to -0.3mmol/l (-0.6 to -0.1) for empagliflozin 10mg versus metformin (Figure S3). Network meta-analysis results similarly showed a reduction of FPG for all SGLT2 inhibitors compared to placebo: -1.9mmol/l (-2.2 to -1.7) for canagliflozin 300mg; -1.6mmol/l (-1.9 to -1.4) for canagliflozin 100mg; -1.5mmol/l (-1.7 to -1.3) for empagliflozin 25mg; -1.4 mmol/l (-1.6 to -1.2) for dapagliflozin 10mg; -1.3mmol/l (-1.6 to -1.1) for empagliflozin 10mg; and -1.1mmol/l (-1.4 to -0.9) for dapagliflozin 5mg (Table 2; Figure 2). Among SGLT2 inhibitors, canagliflozin 300mg reduced FPG to a greater extent compared to all other inhibitors (from -0.8mmol/l versus dapagliflozin 5mg to -0.3mmol/l versus canagliflozin 100mg) (Table 2).

Data on body weight were available from 37 RCTs. Pairwise random-effects meta-analyses showed significant reductions of body weight versus placebo for all SGLT2 treatments, from -2.8kg (-3.2 to -2.4) for canagliflozin 300mg to -1.6kg (-2.1 to -1.0) for dapagliflozin 5mg (Figure S3). When compared to other glucose-lowering drugs, SGLT2 inhibition effects ranged from a -4.4kg (-4.8 to -4.1) reduction for empagliflozin 25mg versus sulphonylurea to -1.2 (-1.9 to -0.6) for dapagliflozin 5mg versus metformin (Figure S3). The results of the network analysis showed a reduction of body weight compared to placebo of -2.5kg (-2.8 to -2.1) for canagliflozin 300mg; -2.3kg (-2.6 to -1.9) for empagliflozin 25mg; -2.2kg (-2.5 to 1.9) for dapagliflozin 10mg; -2.1kg (-2.5 to -1.8) for empagliflozin 10mg; -1.9kg (-2.2 to -1.5) for canagliflozin 100mg; and -1.6kg (-2.0 to -1.2) for dapagliflozin 5mg (Table 2; Figure 2). There was a statistical inconsistency for the body weight network (Table S6); funnel plots for primary outcomes are shown in Figure S6.

Comparable results were found for HbA1c, FPG, and body weight in analyses restricted to studies with a similar duration of follow-up (Table S7).

Secondary cardiometabolic outcomes

Data for other cardiometabolic outcomes ranged from 7828 participants (18 RCTs) for total cholesterol to 17600 participants (33 RCTs) for systolic blood pressure. Compared to placebo, network meta-analysis results showed a reduction of systolic (from -4.9mmHg with canagliflozin 300mg to -2.8mmHg with dapagliflozin 5mg) and diastolic (from -2.0mmHg with canagliflozin 300mg to -1.5mmHg with dapagliflozin 5mg) blood pressure for all SGLT2 inhibitors (Table 2; Figure 2). Canagliflozin 300mg reduced systolic blood pressure to a greater extent compared to other SGLT2 inhibitors, while no differences were found among inhibitors for diastolic blood pressure. All SGLT2 inhibitors slightly increased HDL-cholesterol levels compared to placebo (highest increase, 0.07mmol/l for canagliflozin 300mg and dapagliflozin 10mg), and no differences were found among SGLT2 inhibitors. Canagliflozin at all doses reduced triglycerides levels compared to placebo and empagliflozin while canagliflozin 300mg increased LDL-cholesterol versus placebo and all other SGLT2 inhibitors. No differences were found among SGLT2 for total cholesterol, although data were not available for all treatments (Table 2). There was no statistical inconsistency for all outcomes, although p-values were “borderline” for triglycerides and systolic blood pressure (Table S6).

Safety outcomes

Data on hypoglycaemic events were available from 37 RCTs, reporting a total of 4347 participants with event. The results of the network meta-analysis showed an increased risk of hypoglycaemia compared to placebo for canagliflozin 300mg and 100mg, with respective ORs of 1.6 (1.3 to 1.9) and 1.5 (1.3 to 1.8) (Table 3; Figure S7). Among SGLT2 inhibitors, canagliflozin at both doses significantly increased the risk of hypoglycaemia compared to dapagliflozin 10mg (ORs 1.5) and

empagliflozin 10mg (ORs 1.4) (Table 3). In a sensitivity analysis excluding studies with insulin or sulfonylurea as background therapy, canagliflozin at both doses increased the risk of hypoglycaemia compared to dapagliflozin 10mg (ORs 1.7 to 1.9), although no significant differences were found versus placebo for all SGLT2 inhibitors (Table S8).

Based on 1959 participants with event from all RCTs, network meta-analysis showed an increased risk of urinary tract infection for dapagliflozin 10mg versus placebo and empagliflozin 25mg (ORs 1.4) (Table 3).

Data on genital infection were available from 37 RCTs (1285 participants reporting event). Compared to placebo, there was an increased risk of infection for all SGLT2 inhibitors, with ORs ranging from 4.2 (2.7 to 6.3) for empagliflozin 10mg to 5.9 (4.0 to 8.3) for canagliflozin 300mg. No differences were found among SGLT2 inhibitors (Table 3).

Mean ranks and ranking probabilities are graphically displayed in the Figure S5 and Figure S8, respectively. No inconsistency was found for all three safety outcome networks (Table S6).

Data on diabetic ketoacidosis and bone fractures were reported only in three and nine studies, respectively, limiting the possibility to perform a formal analysis.

DISCUSSION

Several randomised clinical trials have investigated the efficacy and safety of SGLT2 inhibitors compared to placebo or other glucose-lowering drugs (sulphonylurea, DPP-4i, or metformin); however, to date, no direct ‘head-to-head’ trials comparing SGLT2 inhibitors have been reported or are ongoing, thus limiting the possibility of a direct evaluation of their comparative clinical profiles. As network meta-analysis allows indirect assessment between treatments when direct evidence is unavailable, we used this approach to compare SGLT2 inhibitors for multiple outcomes.

While previous network meta-analysis assessed the efficacy and safety of a single SGLT2 inhibitor [58-61] or restricted the analyses only to efficacy outcomes and in patients with type 2 diabetes inadequately controlled with diet and exercise alone or metformin monotherapy [62], we collected data for inhibitors clinically available in most countries and for indicators usually considered when choosing glucose-lowering drugs as well as for other cardiometabolic and safety outcomes to provide a comprehensive picture of these inhibitors.

When compared to placebo, all SGLT2 inhibitors improved glucose control (0.6% to 0.9% decrease in HbA1c and 1.1mmol/l to 1.9mmol/l decrease in FPG) and reduced body weight (1.6kg to 2.5kg), systolic (2.8mmHg to 4.9mmHg), and diastolic (1.5mmHg to 2.0mmHg) blood pressure. Further to this, all SGLT2 inhibitors modestly increased HDL-cholesterol levels compared to placebo (greatest increase, 0.07mmol/l). Available evidence also suggested a small increase in LDL-cholesterol and a reduction of triglycerides with both doses of canagliflozin when compared to placebo. Given the limited data available for total cholesterol, however, the effects of SGLT2 inhibitors on the overall lipid profile should be further investigated. Overall change in these cardiometabolic biomarkers would suggest, at least theoretically, a potential microvascular and cardiovascular benefit. The recent EMPA-REG OUTCOME trial has indeed demonstrated a reduction of cardiovascular events in

patients with type 2 diabetes treated with empagliflozin [63]. On-going RCTs [64, 65] will confirm whether similar benefits could be extended to other drugs of the same class. Conversely, although SGLT2 inhibitors should not increase the risk of hypoglycaemia as they do not stimulate insulin secretion [5], the risk was ~50% greater for both canagliflozin doses but not different for empagliflozin and dapagliflozin when compared to placebo. Of note, the increased canagliflozin risk was nominally lower than metformin and significantly lower than sulphonylurea (~9-fold). Moreover, when the analysis was restricted to studies without background sulphonylureas or insulin, the risk of hypoglycaemia for all SGLT2 inhibitors was similar to placebo. This would suggest an imbalance of insulin or sulphonylurea use across studies where SGLT2 inhibitors were compared to placebo or some heterogeneity possibly due to study design (insulin studies are more likely to be open label and treat-to-target with no stable doses during trial). As expected, the most relevant undesirable effect of SGLT2 inhibition is an increased risk of genitourinary infection as a direct effect of glycosuria. Infections of the upper urinary tract, interestingly, were not consistently increased by SGLT2 inhibitors versus placebo (the risk was increased only by dapagliflozin 10mg), whereas all inhibitors significantly increased the risk of genital infection (balanitis, prothetitis, vulvovaginitis; 4 to 6-fold versus placebo), with no difference across inhibitors.

Along with changes versus placebo, we also found some differences between SGLT2 inhibitors. The highest dose of canagliflozin reduced HbA1c, FPG, and systolic blood pressure to a greater extent compared to dapagliflozin and empagliflozin at any dose. Conversely, highest doses of SGLT2 inhibitors did not differ in the extent of body weight and diastolic blood pressure reduction or HDL-cholesterol increase. Whilst incomplete data on total cholesterol limited a comparative and overall assessment, differences among inhibitors were found for LDL-cholesterol and triglycerides (with the highest dose of canagliflozin decreasing triglycerides versus empagliflozin at any dose and

increasing LDL-cholesterol versus all other SGLT2 inhibitors). Among SGLT2 inhibitors, the risk of urinary tract and genital infection was similar, while at their highest doses canagliflozin increased the risk of hypoglycaemia compared to dapagliflozin also accounting for different background therapies. The differences observed for some clinical outcomes could in part be attributed to outcome definition, study design and/or analysis, or intrinsic pharmacological properties of individual drugs. Indeed, in addition to SGLT2, the SGLT1 receptor has also been implicated in glucose regulation [66], and each inhibitor is known to have a different receptor selectivity profile (for SGLT2 over SGLT1, >2500-fold with empagliflozin; >1200-fold with dapagliflozin; and >250-fold with canagliflozin) [67]. Our findings of a better glucose control and of an increase in LDL-cholesterol by canagliflozin would therefore underline the glicometabolic relevance of SGLT1 inhibition and support recent results on dual SGLT1/SGLT2 blockade [68, 69].

We should acknowledge some limitations of this study. First, we performed a study-level meta-analysis based only on data published in journal articles or available on ClinicalTrials.gov. This could introduce a bias as they are more likely to report ‘positive’ findings compared to unpublished reports. However, such risk of bias should be low for RCTs. Second, in some studies, outcomes were not reported or it was not possible to extract them in a suitable way. Information was retrieved from all 38 RCTs for HbA1c and urinary tract infection and from 37 RCTs for FPG, body weight, hypoglycaemia, and genital infection. Recently, several cases of diabetic ketoacidosis without frank hyperglycaemia (“euglycaemic diabetic ketoacidosis”) have been reported in association with SGLT2 inhibitors [70, 71], along with an increased risk of bone fractures with canagliflozin [72, 73]. Given the limited availability of data on these outcomes, we could not perform formal assessments; future ad-hoc analyses and studies will clarify how such complications are drug- or class-specific. Third, across RCTs, ethnicities of participants included, follow-up durations, or outcomes selection,

definition, and ascertainment could to some extent differ. Yet, the majority of trials used the same classification system for urinary and genital tract infection (system organ class and preferred term, MedDRA). Further to this, analyses for the primary outcomes including studies with similar duration evidenced consistent results. Finally, we found a significant inconsistency for the body weight network (although not present for studies with similar follow-up) and caution is needed in interpreting these results. To our knowledge, this is the first attempt to summarise available data on SGLT2 inhibitors and to assess them comparatively for a wide range of outcomes.

In conclusion, SGLT2 inhibitors improved cardiometabolic markers in patients with type 2 diabetes, with canagliflozin 300mg generally performing better than other inhibitors. However, they increased the risk of genital infection. RCTs with direct SGLT2 comparisons would further delineate their comparative efficacy and tolerability. Moreover, given their effects on blood pressure and lipoproteins, ongoing RCTs with cardiovascular outcomes will clarify whether changes in intermediate biomarkers would also translate into a reduction in relevant vascular complications confirming early positive results of this class of glucose-lowering agents [63, 74].

AUTHOR CONTRIBUTION

FZ, MJD study idea and design

FZ, ZZH, DY literature search and data extraction

FZ data analysis

FZ, DRW, ZZH, DY, KK, MJD study critical revision and manuscript draft

All authors provided final approval of the version to publish. Statistical codes and datasets are available from the corresponding author. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

FUNDING

FZ is a Clinical Research Fellow funded with an unrestricted Educational Grant from Sanofi-Aventis to the University of Leicester. The funding source had no involvement in this study.

ACKNOWLEDGMENTS

We acknowledge the support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care – East Midlands (NIHR CLAHRC – EM), the Leicester Clinical Trials Unit and the NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit, which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

DECLARATION OF INTERESTS

KK has acted as a consultant and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme. He has received grants in support of investigator and investigator initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme. KK has received funds for research, honoraria for speaking at meetings and has served on advisory boards for Lilly, Sanofi-Aventis, Merck Sharp & Dohme and Novo Nordisk.

MJD has acted as consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Janssen and as a speaker for Mitsubishi Tanabe Pharma Corporation. She has received grants in support of investigator and investigator initiated trials from Novo Nordisk, Sanofi-Aventis and Lilly.

DRW has received grant in support of investigator initiated studies and honoraria from Sanofi-Aventis and Novo Nordisk.

All other Authors have no conflict of interests to disclose.

Author Manuscript

REFERENCES

1. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes* 2009; 58:773–795
2. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. *Lancet* 2014; 383:2008–2017
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia* 2015; 58:429–442
4. Abdul-Ghani MA, DeFronzo RA. Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport. *J Intern Med* 2014; 276:352–363
5. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. *Nat Rev Endocrinol* 2012; 8:495–502
6. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. *Pharmacoeconomics* 2008; 26:753–767
7. Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. *Value Health* 2014; 17:157–173
8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009; 62:1006–1012
9. Hoaglin DC HN, Jansen JP, Scott DA, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. *Value Health* 2011; 14:429–437
10. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. *Ann Intern Med* 2015; 162:777–84
11. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *Bmj* 2011; 343:d5928
12. Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J. metan: fixed- and random-effects meta-analysis. *Stata J* 2008; 8:3–28
13. Meta-Analysis MT. Using STATA for network meta-analysis. Available from <http://www.mtm.uoi.gr/index.php/stata-routines-for-network-meta-analysis>. Accessed February 15, 2016
14. White IR. Multivariate random-effects meta-regression: updates to mvmeta. *Stata J* 2011; 11:255–270
15. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. *Res Synth Methods* 2012; 3:111–125
16. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE Decision Support Unit technical support document 2: A generalised linear model framework for pairwise and network meta-analysis of randomised clinical trials. Available from <http://www.nicesdu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf>. Accessed February 15, 2016
17. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. *PloS One* 2013; 8:e76654

18. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* 2011; 64:163–171
19. Jackson D, Barrett JK, Rice S, White IR, Higgins JP. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. *Stat Med* 2014; 33:3639–3654
20. Araki E, Tanizawa Y, Tanaka Y, et al. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. *Diabetes Obes Metab* 2015; 17:665–674
21. Bailey CJ, Iqbal N, T'Joel C, List JF. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. *Diabetes Obes Metab* 2012; 14:951–959
22. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. *BMC Med* 2013; 11:43
23. Bailey CJ, Morales Villegas EC, et al. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. *Diabet Med* 2015; 32:531–541
24. Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. *Diabetes Obes Metab* 2015; 17:294–303
25. Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. *Diabetes Obes Metab* 2014; 16:159–169
26. Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. *Diabetes Care* 2015; 38:1218–1227
27. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. *Diabetes Care* 2015; 38:384–393
28. Del Prato S, Nauck M, Durán-García S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. *Diabetes Obes Metab* 2015; 17:581–590
29. Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. *Diabetes Care* 2013; 36:4015–4021
30. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. *Diabetes Obes Metab* 2014; 16:467–477
31. Haering HU, Merker L, Christiansen AV, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. *Diabetes Res Clin Pract* 2015; 110:82–90
32. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. *Int J Clin Pract* 2012; 66:446–456
33. Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-

week, randomized, double-blind, placebo-controlled, Phase III study. *Expert Opin Pharmacother* 2014; 15:1501–1515

34. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. *Diabetes Care* 2014; 37:740–750
35. Ji L, Ma J, Li H, et al. Dapagliflozin as monotherapy in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. *Clin Ther* 2014; 36:84–100
36. Kadowaki T, Haneda M, Inagaki N, et al. Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. *Adv Ther* 2015; 32:306–318
37. Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. *Diabetes Obes Metab* 2014; 16:1102–1110
38. Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. *Clin Ther* 2015; 37:1773–1788
39. Lavalley-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. *Diabetologia* 2013; 56:2582–2592
40. Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. *J Am Geriatr Soc* 2014; 62:1252–1262
41. Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. *Diabetes Care* 2015; 38:355–364
42. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. *Diabetes Care* 2015; 38:394–402
43. Matthaai S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E. Durability and tolerability of dapagliflozin over 52 ~~week~~ add-on to metformin and sulphonylurea in type 2 diabetes. *Diabetes Obes Metab* 2015; 17:1075–1084
44. Merker L, Häring HU, Christiansen AV, et al. Empagliflozin as add-on to metformin in people with Type 2 diabetes. *Diabet Med* 2015 May 29 [Epub ahead of print]
45. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. *Diabetes Care* 2015; 38:403–411
46. Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. *Lancet Diabetes Endocrinol* 2014; 2:691–700
47. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes Endocrinol* 2013; 1:208–219

48. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycaemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. *Diabetes Care* 2012; 35:1473–1478
49. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycaemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. *Diabetes Care* 2014; 37:1815–1823
50. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added-on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. *Diabetes Obes Metab* 2015; 17:936–948
51. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. *Diabetes Care* 2015; 38:376–383
52. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. *Diabetes Care* 2013; 36:2508–2515
53. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. *Diabetes Obes Metab* 2013; 15:372–382
54. Strojek K, Yoon KH, Hrubá V, Sugg J, Langkilde AM, Parikh S. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. *Diabetes Ther* 2014; 5:267–283
55. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. *Int J Clin Pract* 2013; 67:1267–1282
56. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. *Diabetes Obes Metab* 2014; 16:124–136
57. Mathieu C, Ranetti AE, Li D, et al. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. *Diabetes Care* 2015; 38:2009–2017
58. Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. *Diabetes Obes Metab* 2014; 16:433–442
59. Taieb V, Pacou M, Schroeder M, Schubert A, Nielsen AT. Network Meta-Analysis (NMA) to Assess Relative Efficacy Measured as Percentage of Patients Treated to HbA1c Target with Canagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Metformin and Sulphonylurea (MET+SU). *Value Health* 2015; 18:A598
60. Taieb V, Pacou M, Schroeder M, Nielsen AT, Neslusan C, Schubert A. Bayesian Network Meta-Analysis (NMA) to Assess the Relative Efficacy of Canagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Insulin. *Value Health* 2015; 18:A598.
61. Taieb V, Pacou M, Schroeder M, Nielsen AT, Schubert A, Neslusan C. A Network Meta-Analysis (NMA) to Assess the Longer-Term Relative Efficacy of Canagliflozin in Patients with Type 2 Diabetes Inadequately Controlled on Metformin. *Value Health* 2015; 18:A598

62. Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. *BMJ Open* 2016; 6:e009417
63. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med* 2015; 373:2117–2128
64. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. *Am Heart J* 2013; 166:217–223
65. Available from <https://clinicaltrials.gov/ct2/show/NCT01730534>. Accessed February 15, 2016
66. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. *Journal of internal medicine* 2007; 261:32–43
67. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. *Diabetes Obes Metab* 2012; 14:83–90
68. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. *Clin Pharmacol Ther* 2012;92: 158–169
69. Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. *Diabetes Care* 2015;38: 431–438
70. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. *Diabetes Care* 2015; 38:1687–1693
71. Erondur N, Desai M, Ways K, Meininger G. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. *Diabetes Care* 2015; 38:1680–1686
72. Available at <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM461790.pdf>. Accessed February 15, 2016
73. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. *J Clin Endocrinol Metab* 2016; 101:157–166
74. Wu JHY, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 18 March 2016 [Epub]

TABLES AND FIGURES LEGEND

Table 1: Baseline characteristics of the included studies

Table 2: Comparisons of SGLT2 inhibitors for cardiometabolic outcomes

Table 3: Comparisons of SGLT2 inhibitors for safety outcomes

Figure 1: Network maps for cardiometabolic and safety outcomes

Legend: Nodes represent the competing treatments and their size is proportional to the number of participants; edges represent the available direct comparisons between pairs of treatments and their width is proportional to the number of trials comparing every pair.

Abbreviations


Cana100=Canagliflozin 100mg; Cana300=Canagliflozin 300mg; Dapa5=Dapagliflozin 5mg; Dapa10=Dapagliflozin 10mg; Empa10=Empagliflozin 10mg; Empa25=Empagliflozin 25mg; DPP-4i= Dipeptidyl peptidase-4 inhibitor; Met=Metformin; SU=Sulphonylurea

Figure 2: Differences vs Placebo (dotted lines) in cardiometabolic outcomes for the drugs included in the network meta-analysis

Abbreviations


Cana100=Canagliflozin 100mg; Cana300=Canagliflozin 300mg; Dapa5=Dapagliflozin 5mg; Dapa10=Dapagliflozin 10mg; Empa10=Empagliflozin 10mg; Empa25=Empagliflozin 25mg; DPP-4i= Dipeptidyl peptidase-4 inhibitor; Met=Metformin; SU=Sulphonylurea

Figure 1



dom-16-0138-op-File005.tif

Figure 2: Differences vs Placebo (dotted lines) in cardiometabolic outcomes for the drugs included in the network meta-analysis



Abbreviations: Cana300=Canagliflozin 300mg; Cana100=Canagliflozin 100mg; Dapa10=Dapagliflozin 10mg; Dapa5=Dapagliflozin 5mg; Empa25=Empagliflozin 25mg; Empa10=Empagliflozin 10mg; DPP-4i=Dipeptidyl peptidase-4 inhibitor; Met=Metformin; SU=Sulphonylurea

dom-16-0138-op-File006.TIF



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Zaccardi, F;Webb, DR;Htike, ZZ;Youssef, D;Khunti, K;Davies, MJ

Title:

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis

Date:

2016-08

Citation:

Zaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D., Khunti, K. & Davies, M. J. (2016). Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. *DIABETES OBESITY & METABOLISM*, 18 (8), pp.783-794. <https://doi.org/10.1111/dom.12670>.

Persistent Link:

<http://hdl.handle.net/11343/291311>